Edition:
United States

ARIAD Pharmaceuticals Inc (ARIA.OQ)

ARIA.OQ on NASDAQ Stock Exchange Global Select Market

10.77USD
1:20pm EDT
Change (% chg)

$0.17 (+1.60%)
Prev Close
$10.60
Open
$10.54
Day's High
$10.84
Day's Low
$10.51
Volume
368,799
Avg. Vol
964,812
52-wk High
$10.84
52-wk Low
$4.38

ARIA.OQ

Chart for ARIA.OQ

About

ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the... (more)

Overall

Beta: 1.90
Market Cap(Mil.): $2,042.76
Shares Outstanding(Mil.): 192.71
Dividend: --
Yield (%): --

Financials

  ARIA.OQ Industry Sector
P/E (TTM): -- 38.67 37.29
EPS (TTM): -0.33 -- --
ROI: -12.15 0.12 14.33
ROE: -- -1.96 15.28

BRIEF-Ariad Pharmaceuticals completes strategic review, reaffirms 2016 outlook

* Outcomes of strategic review includes significant reduction in company's expense base

Jun 17 2016

BRIEF-Ariad initiates submission of NDA for Brigatinib to FDA ahead of plan

* Rolling NDA submission is expected to be complete in Q3 of 2016.

Jun 17 2016

BRIEF-Ariad provides long-term data on cancer drug, Iclusig

* Overall survival at four years is estimated to be 77 percent

Jun 13 2016

BRIEF-Ariad Pharmaceuticals says CEO Harvey Berger's 2015 compensation was $10.1 mln - SEC filing

* Says CEO Harvey Berger's 2015 total compensation was $10.1 million versus $5.1 million in 2014 - SEC filing Source text for Eikon: [ID:(http://1.usa.gov/218q1Le )] Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jun 08 2016

BRIEF-Incyte Corp amends buy-in license deal entered into by Ariad Pharmaceuticals

* On june 1, 2016, amended buy-in license deal entered into by ariad pharmaceuticals, ariad pharmaceuticals (europe) s.a.r.l. & co

Jun 01 2016

BRIEF-Ariad Pharmaceuticals announces pricing, reimbursement for iclusig in France

* Ariad announces pricing and reimbursement for iclusig in France

May 19 2016

BRIEF-Ariad Pharmaceuticals posts Q1 loss per share $0.28

* Ariad reports first quarter 2016 financial results and progress on strategic review

May 10 2016

BRIEF-Ariad Pharmaceuticals says board approved increase in size of board to eleven directors

* Effective as of May 4, 2016, board approved an increase in size of board from nine to eleven directors - sec filing

May 06 2016

U.S. activist investors finding fewer opportunities; compromise more common

By Svea Herbst-Bayliss, Lawrence Delevingne and Michael Flaherty

Apr 19 2016

U.S. activist investors finding fewer opportunities; compromise more common

By Svea Herbst-Bayliss, Lawrence Delevingne and Michael Flaherty

Apr 19 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : S&P Capital IQ Quantitative Report
$127.00
Provider : Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.